Title: Developing Intranasal Inhalation therapies for the treatment of inflammatory and infectious disease of the respiratory system

Abstract:

Title : Developing Intranasal Inhalation therapies for the treatment of inflammatory and infectious disease of the respiratory system Developing intranasal/inhalation therapies for the treatment of inflammatory and infectious disorders of the pulmonary system Disorders affecting the respiratory system including allergies, asthma, and upper respiratory infections are a major course of morbidity and mortality in the US. For years it has been accepted that dysregulation of the nasal alternating turgescence of the inferior turbinates may lead to the development of respiratory disorders. Intranasal therapies seem to provide a great means to deliver treatments to regulate the nasal cycles as well as modulate the mucosal microbiome. In a from molecules to population fashion, the present seminar explores the development of intranasal therapies using candidate substances displaying, anti-inflammatory, antiviral, and microbiome modulating effects. The overarching goal of this research agenda is to develop effective interventions to improve the quality of life of those suffering from Pulmonary Disorders. To this end, a series of basic, translational, applied, and clinical studies have been designed to unveil the therapeutic properties of Xylitol, Chlorphenamine, and grapefruit seed extract from the successful management and treatment of both inflammatory and infectious disorders of the pulmonary system. At the end of the seminar, the audience will be able to: • Recite the importance of the nasal cycle and the nasal microbiome as they relate to pulmonary health • Recall the different phases of the therapeutic pipeline in the context of pulmonary disorders • Identify the therapeutic properties of Xylitol, Chlorphenamine, and grapefruit seed extract • Construct a roadmap of the development of intranasal/inhalation therapies for the treatment of pulmonary disorders.


 

Biography:

Marcos A. Sanchez-Gonzalez, MD, PhD, He run his own company and he is Chief Scientific Officer Company: Dr. Ferrer BioPhrama Mismi FL

Title: The Hybrid Survey on the Acceptance and Affordability of COVID 19 Vaccine among the People of Konnagar- Uttarpara Belt, West Bengal, India- A Survey Based Study

Abstract:

A Hybrid Survey on the Acceptance and Affordability of COVID 19 Vaccine among the People of Konnagar- Uttarpara Belt, West Bengal, India- A Survey Based Study

Overview: Currently, multiple vaccines for coronavirus disease 2019 (COVID-19) are in clinical trials and in the market. In Dec 2020 to Feb 2021, 1543 individuals in konnagar- Uttarpara belt, West Bengal surveyed to evaluate possible acceptance rates, affordability and factors affecting the acceptance of a vaccine for COVID-19.

Method of Study: Questionnaire is prepared, 1200 in physical format and also as the google form. The form is circulated physically and digitally among the people and then we have collected the data in excel. Based on the result we have prepared our statistical graphs.

Result 

Physical Survey [n= 1100]: 94.4 percent of respondents reported that they would be very or very likely to take a vaccine for COVID-19, 4.8 percent don’t want to take vaccine and 0.8 don’t know about their decision. In that 91.2 percent respondents want to take Indian Vaccine; 2.2 percent respondents want to take foreign vaccine. Other respondents can take any vaccine. The affordability, majority needs a vaccine which cost less than 500 INR and it should be regulated by government.

Digital Survey [n=443]: Result 94.1 percent of respondents reported that they would be very or very likely to take a vaccine for COVID-19, 5.19 percent don’t want to take vaccine and 0.71 don’t know about their decision. In that 85 percent respondents want to take Indian Vaccine; 3.6 percent respondents want to take foreign vaccine. Other respondents can take any vaccine The affordability, majority needs a vaccine which cost less than 500 INR and it should be regulated by government.

Conclusion: Majority of Responders want a COVID 19 vaccine. Majority responders want Indian COVID19 Vaccine. Majority responders want a vaccine in a cost of below 500 INR.

Biography:

Dattatreya Mukherjee, he studied  MBBS and worked as Research Assistant and Undergraduate research scholar
at Jinan University which is located at  P.R China.